Intravenous Paracetamol and Patent Ductus Arteriosus Closure

Authors

  • Dora Darussalam Neonatology Division, Department of Child Health, Medical School, Syiah Kuala University, Zainoel Abidin Hospital, Banda Aceh, Indonesia .
  • Herlina Dimiati Pediatric Cardiology Division, Department of Child Health, Medical School, Syiah Kuala University, Zainoel Abidin Hospital, Banda Aceh, Indonesia
  • Isra Firmansyah Neonatology Division, Department of Child Health, Medical School, Syiah Kuala University, Zainoel Abidin Hospital, Banda Aceh, Indonesia
Abstract:

Background: Standard medical treatments for patent ductus arteriosus (PDA) closure are, including indomethacin/ibuprofen and surgical ligation. Nowadays, a new strategy to close PDA is the use of paracetamol. The present study aimed to describe the use of intravenous (IV) paracetamol for PDA closure in neonates who present a contraindication to ibuprofen or ibuprofen failure with no possibility to perform surgical ligation due to major instability.Methods: The present study was conducted from January to December 2017 in the neonatal intensive care unit of Dr. Zainoel Abidin Hospital and Harapan Bunda Hospital, Banda Aceh, Indonesia, on neonates with hemodynamic significant PDA (hsPDA). All the subjects received IV paracetamol (15 mg/kg every 6 h) for 3 days. Thereafter, the ductus was evaluated by echocardiography on the 5th day after the regiment.Results: A total of 72 neonates were diagnosed with hsPDA and their average of gestational age was 34.26 weeks and their average of birth weight was 1945.69 g for 39 (54.2%) female neonates, 33 (45.8%) male neonates, 45 (62.5%) premature infants, and 27 (37.5%) full-term infants. About 26 (36.1%) infants had a closed PDAs on the 5th days of evaluation, 11 (15.3%) infants had regiment twice for closed PDA at the 10th days of evaluation, and 35 (48.6%) neonates had more closed PDA after three or four regiments. Successful closure with paracetamol was achieved in 51(70.8%) neonates, while 21 (29.2%) neonates failed the PDA closure.Conclusion: Based on the findings of the present study, IV paracetamol appears to be reasonably effective for PDA closure in both preterm and term infants. This should be the first-line of therapy choice when there are contraindications for the treatment with ibuprofen.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Paracetamol for Closure of Patent Ductus Arteriosus.

Paracetamol can be used cautiously as the first line drug in the absence of indomethacin/ibuprofen or when these drugs are contraindicated. Larger studies comparing paracetamol versus indomethacin/ibuprofen in symptomatic PDA may be needed before paracetamol can be accepted as the first line drug in treatment of PDA. It would be worthwhile to also follow-up this cohort to see the neuro-developm...

full text

Efficacy and complications of oral ibuprofen and intravenous acetaminophen in closure of patent ductus arteriosus of preterm neonates

Background: Previous studies have considered patent ductus arteriosus (PDA) a common finding in premature infants, leading to complications such as intracranial hemorrhage, necrotizing enterocolitis and pulmonary dysplasia. The aim of this study was to assess and compare the efficacy of oral ibuprofen and intravenous acetaminophen in the closure of arterial duct in premature newborns. We also e...

full text

Transfemoral plug closure of patent ductus arteriosus.

A patent ductus arteriosus should be closed because of its hemodynamic significance and/or the risk of infective endocarditis. Mortality of surgery is low. In adults, however, technical problems can arise due to calcification of the ductus walls. Using the transfemoral plug technique, developed by Porstmann, we attempted a ductus closure without surgery on 35 patients. The youngest was an 11-ye...

full text

Transcatheter Closure of Patent Ductus Arteriosus

Background The USCI PDA Umbrella is a device to close patent ductus arteriosus (PDA) by a transcatheter technique. Human clinical trials have shown excellent efficacy in reducing or eliminating the PDA shunt, but concerns remain about the risk of infection with this device. The purpose of this study was to evaluate the risk of infection using an animal model. Methods and Results Susceptibility ...

full text

Transcatheter Closure of Patent Ductus Arteriosus

Patent ductus arteriosus (PDA) constitutes 6 to 11% of all congenital heart defects. While surgical ligation and video-assisted, thoracoscopic interruption of PDA are still available, transcatheter occlusion of PDAs has recently assumed a major role in closure of PDA. A large number of devices have been designed and tested both in animal models and human subjects, but only few devices (free and...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 11  issue 1

pages  31- 35

publication date 2020-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023